;slkjdf
COVID-19 Impact : Our team has been closely monitoring the current developments to identify the potential impact of COVID-19 on stakeholders and business processes across the value chain of industries. A special section about COVID-19 will be covered with the report to help companies in defining sustainable strategies.
Introduction
Anticonvulsants are used in the treatment of epileptic seizures, neuropathic pain, and mood stabilizers in the treatment of psychiatric disorders, such as bipolar disorder. Anticonvulsant drugs are developed for the treatment of epilepsy, a neurological condition, which affects around 50 million people worldwide. Several new Anticonvulsant drugs are under clinical trials, and some of the approved drugs have been investigated for pain relief and psychiatric disorders. Some of these indications have been approved.
The Anticonvulsants market is driven by the increasing availability of the drug in the market, growing awareness about anticonvulsants, patent expiration of many blockbuster drugs, and the three trends involving consumption of AEDs, which are issues of generic substitution of AEDs, pharmacogenomics predicting serious adverse events in certain ethnic population, and the issue of suicide risk involving the entire class of AEDs. The issue of suicide risk associated with the entire class of AEDs, along with high costs and the unavailability of generic and branded anticonvulsants, is restraining the growth of novel therapies in the anticonvulsants market.
Product Type Outlook
Based on product type, the market is segmented into Barbiturates, Aldehydes, Benzodiazepines, Carboxamides, and Bromides. Barbiturates also have proconvulsant actions; some barbiturates can have both proconvulsant and anticonvulsant properties, with low dosage associated with seizure activity in epilepsy patients while higher doses leading to burst suppression. Moreover, Benzodiazepines are helpful in controlling or preventing convulsions or seizures
Regional Outlook
Based on regions, the anticonvulsants market is categorized into North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, & Rest of the World. North America is anticipated to hold the largest market share owing to the presence of a well-developed healthcare infrastructure and growing spending on research and development, which are contributing to the growth of the market. The Asia Pacific region is expected to witness the fastest growth in the anticonvulsants market due to extensive spending in healthcare and improving healthcare infrastructure, along with increasing government spending and growing demand for drugs in this region.
Market Players
The key leading players in the market include Pfizer inc., Novartis International AG, Abbott Laboratories, UCB, Johnson & Johnson, GlaxoSmithKline Pharmaceuticals Ltd, Cephalon Inc, Shire plc.
What Does This Report Provide?
This report provides a detailed understanding of the global Anticonvulsants market from qualitative and quantitative perspectives during the forecast period. The report also provides dynamic indicators with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.
Market Segmentation:
By Product Type
By Region:
Reasons to Buy This Report:
Customization:
We provide customization of the study to meet specific requirements:
For more information, contact: [email protected]
Single User (PDF)
3850Multi User (PDF)
5150Enterprise User (PDF)
7650Avail customized purchase options to meet your exact research needs.
Detailed scope covering all the major segments in the market
In line data validations to ensure data precision
Market recommendations supporting decision making processes
Round the clock analyst support to resolve your queries
Up to 15% additional free customization to meet your specific requirements
IN +91 706 672 5858